Related references
Note: Only part of the references are listed.Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma
Samantha E. Bowyer et al.
MELANOMA RESEARCH (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma
Victoria J. Mar et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
Victoria J. Mar et al.
CLINICAL CANCER RESEARCH (2013)
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma
Anna Richter et al.
SCIENTIFIC REPORTS (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Michael Krauthammer et al.
NATURE GENETICS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Determinants of BRAF mutations in primary melanomas
JL Maldonado et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma
DC Whiteman et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
